If You Invested in Synlogic (SYBX)

Synlogic, Inc. (Nasdaq: SYBX) is a biopharmaceutical company that focuses on advancing novel therapeutics to transform the care of serious diseases in need of new treatment options. The company is classified under pharmaceutical preparation manufacturing within the broader manufacturing sector. Synlogic designs, develops and manufactures its drug candidates by applying precision genetic engineering to well-characterized probiotics, creating orally administered, gastrointestinal (GI)-restricted biotherapeutics.

According to company disclosures, Synlogic’s work has centered on rare metabolic diseases and other conditions where disease-specific metabolites pass through the GI tract. Its approach has involved engineering probiotics to consume or modify specific biological targets in the gut, with the goal of addressing inborn errors of metabolism and other serious disorders. The company has described this platform as enabling GI-restricted, oral medicines designed to act locally in the gastrointestinal tract.

Therapeutic focus and disease areas

Synlogic has reported a focus on rare metabolic diseases such as phenylketonuria (PKU) and classical homocystinuria (HCU), both of which are inborn errors of metabolism with significant unmet medical need. The company has also described early-stage research and development efforts in areas including enteric hyperoxaluria, gout, cystinuria and inflammatory bowel disease (IBD). These programs have been based on the same Synthetic Biotic concept of using engineered probiotics to consume or alter disease-related metabolites in the GI tract.

In earlier communications, Synlogic identified labafenogene marselecobac (SYNB1934) as a potential treatment for PKU and SYNB1353 as a potential treatment for classical HCU. The company has reported preclinical and clinical data for SYNB1353, including evidence of methionine degradation in preclinical models and a healthy volunteer study, as well as a proof-of-mechanism signal for lowering methionine, a precursor to homocysteine. Regulatory designations disclosed for SYNB1353 include Rare Pediatric Disease Designation, Fast Track designation and Orphan Drug Designation from the U.S. Food and Drug Administration for the potential treatment of HCU.

Clinical development and strategic shift

Synlogic has described itself as a clinical-stage biotechnology company, with late-stage development historically focused on PKU. The company initiated Synpheny-3, a global, pivotal Phase 3 clinical trial evaluating SYNB1934 as a potential treatment for PKU, with a design that included dose escalation, a randomized withdrawal period and an open-label extension. The trial’s primary endpoint was defined as a change in phenylalanine levels in responders, reflecting the company’s emphasis on metabolite control as a therapeutic goal.

In February 2024, Synlogic announced the decision to discontinue Synpheny-3 after an internal data review indicated the study was unlikely to meet its primary endpoint. The company stated that this decision was not based on safety or tolerability concerns but on efficacy expectations. As part of the same update, Synlogic reported that it would cease operations and reduce its workforce by more than 90%, retaining only certain employees to assist in the strategic review process and the discontinuation of the study. The Board of Directors indicated that it would evaluate strategic options, including potential acquisitions, mergers, reverse mergers, sales of assets, dissolution or other strategic transactions.

Strategic alternatives and corporate actions

Following the decision to discontinue Synpheny-3, Synlogic’s Board initiated a process to explore and evaluate strategic alternatives intended to enhance shareholder value. Company communications describe the engagement of financial advisors, including Ladenburg Thalmann & Co. Inc. and Lucid Capital Markets, LLC, to assist in reviewing options such as an acquisition, merger, business combination or other strategic transaction. Synlogic has emphasized that there can be no assurance that this process will result in any transaction.

In February 2024, the Board adopted a limited duration stockholder rights plan, sometimes referred to as a rights plan, in response to an unsolicited accumulation of Synlogic shares by an investor. The company stated that this plan was intended to protect stockholders while the Board and management evaluated strategic alternatives, by reducing the likelihood that any person or group could gain control of Synlogic through open market accumulation without paying an appropriate control premium or allowing sufficient time for Board deliberation.

Collaborations and external relationships

Synlogic has reported research collaborations and contracts that support its Synthetic Biotic platform and manufacturing capabilities. These include a research collaboration with Roche focused on discovering a novel Synthetic Biotic for the treatment of inflammatory bowel disease, under which Synlogic has disclosed receiving milestone payments. The company has also described a collaboration with Ginkgo Bioworks in synthetic biology, which contributed to the development of SYNB1353 and at least one other pipeline program.

In addition, Synlogic announced an approximately $1 million subcontract under a U.S. Air Force Research Laboratory (AFRL) prime contract to develop a manufacturing process to support development of a potential live probiotic product. This work was described as an extension of earlier efforts under the Air Force Synthetic Biology Challenge with the Massachusetts Institute of Technology, highlighting the company’s experience in process development and manufacturing for synthetic biology-based therapeutics.

Corporate governance and shareholder matters

Synlogic is incorporated as a U.S. public company and files reports with the U.S. Securities and Exchange Commission. Its definitive proxy statement for the 2025 annual meeting describes a board structure with classified directors and outlines proposals such as the election of directors, advisory votes on executive compensation, approval of an equity incentive plan and ratification of the independent registered public accounting firm.

An 8-K filing dated December 15, 2025, reports that stockholders approved the Synlogic, Inc. 2025 Equity Incentive Plan at the 2025 annual meeting. The 2025 plan succeeded the company’s 2015 Equity Incentive Award Plan and authorizes the issuance of shares of common stock, including shares that may become available if awards under the prior plan are cancelled or expire. The same filing details stockholder voting outcomes on director elections, executive compensation and the appointment of KPMG LLP as independent registered public accounting firm.

Business model and segment reporting

Synlogic has stated that it operates in a single segment focused on the discovery and development of Synthetic Biotics. Revenue historically has been associated with research collaborations and agreements, including work with Roche and a material transfer agreement described in financial results. The company’s primary activities have involved research and development, clinical trials, manufacturing process development and related general and administrative functions to support its biotechnology operations.

While Synlogic has announced plans to cease operations and undertake a substantial workforce reduction as part of its strategic review, its public filings and disclosures continue to describe the company’s historical focus on Synthetic Biotic therapeutics, rare metabolic diseases and GI-restricted, orally administered biotherapeutics based on engineered probiotics. Investors and researchers reviewing Synlogic, Inc. (SYBX) should consider both the company’s scientific and clinical history and the ongoing evaluation of strategic alternatives when assessing the stock.